

Biotin Conjugated Anti-Human CD33 Antibody [PSH05-26]

HA722599B



Product Type:	Recombinant Rabbit monoclonal IgG, primary antibodies
Species reactivity:	Human
Applications:	ELISA(Det)
Molecular Wt:	Predicted band size: 40 kDa
Clone number:	PSH05-26

Description: CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins. CD33 can be stimulated by any molecule with sialic acid residues such as glycoproteins or glycolipids. Upon binding, the immunoreceptor tyrosine-based inhibition motif (ITIM) of CD33, present on the cytosolic portion of the protein, is phosphorylated and acts as a docking site for Src homology 2 (SH2) domain-containing proteins like SHP phosphatases. This results in a cascade that inhibits phagocytosis in the cell.

Conjugate: Biotin-conjugated

Immunogen: Recombinant protein within human CD33 aa 18-259 (P20138).

Positive control: Recombinant Human CD33 protein (HA210949).

Subcellular location: Cell membrane; Peroxisome.

Database links: SwissProt: P20138 Human

Recommended Dilutions:

ELISA(Det) Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit monoclonal [PSH05-25] to Human CD33 (Capture) (HA722254) and Recombinant Human CD33 protein (HA210949) as the standard. The reference range value is 22.6-5500pg/ml.

Storage Buffer: PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% ProClin300.

Storage Instruction: Shipped at 4°C. Store at +4°C short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20°C long term.

Purity: Protein A affinity purified.

Hangzhou Huaan Biotechnology Co., Ltd.

Orders:0086-571-88062880

Technical:0086-571-89986345

Service mail:support@huabio.cn

华安生物
HUABIO
www.huabio.cn

No Images

Note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE".

Background References

1. Albinger N et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. *Blood Cancer J.* 2022 Apr
2. Willier S et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. *Blood.* 2021 Feb

Hangzhou Huaan Biotechnology Co., Ltd.

Orders:0086-571-88062880

Technical:0086-571-89986345

Service mail:support@huabio.cn

 华安生物
HUABIO
www.huabio.cn